In patent litigation surrounding cases that concern multiple technologies, a common process for invalidating a patent under Title 35 of the U.S. Code, Section 103(a) for apparent reasons is pretty direct. Nevertheless, according to Roy Wepner of Rutgers, matters become rather complex when it comes to patent challengers in the chemical and pharmaceutical domains. The issue at hand? A ‘lead compound’ rule for prior art, which Wepner argues not only contravenes several U.S. Supreme Court rulings but is also antithetical to public policy.
This ‘lead compound’ rule creates an added difficulty in disproving a patent on apparent grounds. Wepner argues that this rule is inherently misjudged under the law. He criticizes its constrictions on patent challengers, thereby underscoring the tension between public policy and established norms in the patent litigation landscape.
Given the combination of the richness of the chemical and pharmaceutical sectors and the growing prominence of patent litigations, this rule has the potential to be a significant concern, an argument clearly articulated by Wepner. As such, it would be prudent for professionals in the field to consider his perspective seriously outlined in his recent piece.